CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients.

导出 OA

翻译打印收藏纠错

作者： Francesca,Schiano di Cola ^[1] ; Salvatore,Caratozzolo ^[2] ; Marco,Bolchini ^[3] ; Giulia,Ceccardi ^[3] ; Matteo,Cortinovis ^[3] ; Paolo,Liberini ^[3] ; Alessandro,Padovani ^[3] ; Renata,Rao ^[3]

作者单位： Clinical and Experimental Sciences Department, Neurology Unit, University and SpedaliCivili, Brescia, Italy. francescaschiano@hotmail.it. ^[1] Clinical and Experimental Sciences, Università Degli Studi Di Brescia, ASST Spedali Civili Brescia, Piazzale Spedali Civili, 1, 25123, Brescia, Brescia (BS), Italy. francescaschiano@hotmail.it. ^[2] Clinical and Experimental Sciences Department, Neurology Unit, University and SpedaliCivili, Brescia, Italy. ^[3]

关键词 CGRP Disability Erenumab Migraine Prophylaxis

主题词抗体, 单克隆(Antibodies, Monoclonal);降钙素基因相关肽(Calcitonin Gene-Related Peptide);人类(Humans);偏头痛(Migraine Disorders)

DOI 10.1007/s10072-022-06154-0

PMID 35618933

发布时间 2022-08-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交